QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 15 July 2020SV NewsSV Health Investors announces the appointment of Allan May and Ryan Pierce as venture partners to the Medtech Convergence Fund
- 13 July 2020SV NewsPaul LaViolette Appointed to Edwards Lifesciences Board of Directors
- 6 July 2020Portfolio NewsAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
- 1 July 2020Portfolio NewsQurAlis Announces Agreement to Strengthen ALS Pipeline
- 1 July 2020Portfolio NewsEvidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health
- 24 June 2020Portfolio NewsClarify Medical Appoints John E. Schellhorn as President and Chief Executive Officer
- 23 June 2020Portfolio NewsSV Health Investors notes Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
- 23 June 2020Portfolio NewsBicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
- 23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK
- 22 June 2020Portfolio NewsDeciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- 17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
- 11 June 2020Portfolio NewsX4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer